Mission statement

ATLAB Pharma aims at developing radioimmunotherapy as a breakthrough in cancer treatment.

Radioimmunotherapy is a tumor-specific delivery system using monoclonal antibodies conjugated to radioisotopes (radio-antibodies) to target radiation to cancer cells wherever they have disseminated in the body, thus expanding the well-proven efficacy of radiotherapy from localized tumors to metastatic cancers.

ATLAB Pharma is at the forefront of developing safe and efficient radio-antibodies based on new generation therapeutic radioisotopes Lutetium-177 and Astatine-211.

ATLAB Pharma lead drug candidate, ATL101, has been shown to have a favorable safety profile and anti-tumor activity in Phase I and Phase II clinical trials in patients with castrate-resistant prostate cancer.



:: Latest news ::
  • 3 Oct 2013 - Tolerance and efficacy of anti-PSMA fractionated radioimmunotherapy with ATL101 in metastatic castrate resistant prostate cancer (mCRPC) presented at the European Cancer Congress ECC 2013. Read more...

  • 11 Apr 2013 - Prostate specific membrane antigen (PSMA) imaging as predictive biomarker for anti-PSMA radioimmunotherapy in metastatic castration-resistant prostate cancer patients presented at AACR 2013. Read more...
  • 15 Feb 2013 - Favorable safety profile and antitumor activity of ATL101 (Lutetium-177 anti-PSMA antibody) in castration-resistant prostate cancer patients presented at ASCO GU 2013. Read more...